You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 10,828,298

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,828,298

Title:	Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsu- lfonyl)acetamide
Abstract:	A stabilized solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide is provided, namely, a solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide and D-mannitol having a specific surface area of 1.0 m.sup.2/g or less.
Inventor(s):	Furuta; Shouji (Kyoto, JP), Mukai; Hironori (Kyoto, JP)
Assignee:	NIPPON SHINYAKU CO., LTD. (Kyoto, JP)
Application Number:	16/044,821
Patent Claims:	1. A tablet comprising: 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide; and D-mannitol having a specific surface area of larger than 0.2 m.sup.2/g and smaller than 0.7 m.sup.2/g; wherein the content of D-mannitol is: (a) such that the weight of D-mannitol is from 5 to 10000 parts by weight with respect to 1 part by weight of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide, (b) from 10 to 99 wt % of the total weight of the tablet, and (c) 20 wt % or more of the total weight of diluents contained in the tablet. 2. The tablet according to claim 1, wherein the amount of D-mannitol is from 10 to 9500 parts by weight with respect to 1 part by weight of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide. 3. The tablet according to claim 1, wherein the amount of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide is from 0.1 to 2 wt % of the total weight of the tablet. 4. The tablet according to claim 3, wherein the amount of D-mannitol is from 15 to 95 wt % of the total weight of the tablet. 5. The tablet according to claim 3, further comprising one substance selected from the group consisting of cornstarch, sucrose, and crystalline cellulose. 6. The tablet according to claim 3, further comprising hydroxypropyl cellulose. 7. The tablet according to claim 3, further comprising magnesium stearate. 8. The tablet according to claim 4, further comprising one substance selected from the group consisting of cornstarch, sucrose, and crystalline cellulose. 9. The tablet according to claim 4, further comprising hydroxypropyl cellulose. 10. The tablet according to claim 4, further comprising magnesium stearate. 11. The tablet according to claim 8, further comprising hydroxypropyl cellulose. 12. The tablet according to claim 8, further comprising magnesium stearate. 13. The tablet according to claim 11, further comprising magnesium stearate. 14. The tablet according to claim 1, wherein the amount of D-mannitol is from 15 to 95 wt % of the total weight of the tablet. 15. The tablet according to claim 1, further comprising one substance selected from the group consisting of cornstarch, sucrose, and crystalline cellulose. 16. The tablet according to claim 15, further comprising hydroxypropyl cellulose. 17. The tablet according to claim 15, further comprising magnesium stearate. 18. The tablet according to claim 1, further comprising hydroxypropyl cellulose. 19. The tablet according to claim 1, further comprising magnesium stearate. 20. The tablet according to claim 1, which is used for treating pulmonary arterial hypertension. 21. A method for treating pulmonary arterial hypertension, the method comprising the step of administering the tablet according to claim 1 to a subject. 22. A method for treating pulmonary arterial hypertension, the method comprising the step of administering the tablet according to claim 3 to a subject. 23. A method for treating pulmonary arterial hypertension, the method comprising the step of administering the tablet according to claim 4 to a subject. 24. A method for treating pulmonary arterial hypertension, the method comprising the step of administering the tablet according to claim 8 to a subject. 25. A method for treating pulmonary arterial hypertension, the method comprising the step of administering the tablet according to claim 11 to a subject. 26. A method for treating pulmonary arterial hypertension, the method comprising the step of administering the tablet according to claim 17 to a subject. 27. A method for treating pulmonary arterial hypertension, the method comprising the step of administering the tablet according to claim 12 to a subject. 28. A method for treating pulmonary arterial hypertension, the method comprising the step of administering the tablet according to claim 13 to a subject.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.